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Abstract
Background: Established risk factors for prostate cancer have not translated to effective prevention or adjuvant
care strategies. Several epidemiologic studies suggest greater body adiposity may be a modifiable risk factor for
high-grade (Gleason 7, Gleason 8-10) prostate cancer and prostate cancer mortality. However, BMI only
approximates body adiposity, and may be confounded by centralized fat deposition or lean body mass in older
men. Our objective was to use bioelectric impedance analysis (BIA) to measure body composition and determine
the association between prostate cancer and total body fat mass (FM) fat-free mass (FFM), and percent body fat (%
BF), and which body composition measure mediated the association between BMI or waist circumference (WC)
with prostate cancer.
Methods: The study used a multi-centered recruitment protocol targeting men scheduled for prostate biopsy. Men
without prostate cancer at biopsy served as controls (n = 1057). Prostate cancer cases were classified as having
Gleason 6 (n = 402), Gleason 7 (n = 272), or Gleason 8-10 (n = 135) cancer. BIA and body size measures were
ascertained by trained staff prior to diagnosis, and clinical and comorbidity status were determined by chart
review. Analyses utilized multivariable linear and logistic regression.
Results: Body size and composition measures were not significantly associated with low-grade (Gleason 6) prostate
cancer. In contrast, BMI, WC, FM, and FFM were associated with an increased risk of Gleason 7 and Gleason 8-10
prostate cancer. Furthermore, BMI and WC were no longer associated with Gleason 8-10 (ORBMI = 1.039 (1.000,
1.081), ORWC = 1.016 (0.999, 1.033), continuous scales) with control for total body FFM (ORBMI = 0.998 (0.946, 1.052),
ORWC = 0.995 (0.974, 1.017)). Furthermore, increasing FFM remained significantly associated with Gleason 7 (ORFFM
= 1.030 (1.008, 1.052)) and Gleason 8-10 (ORFFM = 1.044 (1.014, 1.074)) after controlling for FM.
Conclusions: Our results suggest that associations between BMI and WC with high-grade prostate cancer are
mediated through the measurement of total body FFM. It is unlikely that FFM causes prostate cancer, but instead
provides a marker of testosterone or IGF1 activities involved with retaining lean mass as men age.
Background
Prostate cancer is the leading cancer diagnosis, and the
second-leading cause of cancer-related death, among U.
S. men [1]. The American Cancer Society estimates over
240,000 new cases will be diagnosed in 2011, with
almost 34,000 deaths attributed to the disease [1]. High
prevalence and mortality, as well as the long period of
time to tumor development, make prostate cancer an
attractive target for prevention. However, little is certain
about what causes prostate cancer, or the best preven-
tion approach. Established risk factors such as age, Afri-
can American race, family history of disease, or genetic
variants identified from genome wide association studies
have not as yet advanced the development of individua-
lized screening and prevention strategies. At present,
early-detection and treatment is emphasized, often
through prostate-specific antigen (PSA) testing. How-
ever, PSA testing does not differentiate between poten-
tially fatal and non-fatal prostate cancer, and the vast
majority of men with localized disease diagnosed in the
PSA era are treated unnecessarily for non-life-threaten-
ing cancers [2]. Furthermore, the U.S. Food and Drug
Administration recently concluded that drugs such as
finasteride reduce the risk of low-grade cancer but do
not have a favorable risk-benefit profile suitable for
broad administration [3]. Thus, new strategies are
needed to understand the causes of advanced prostate
cancer and who may be most at risk.
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Obesity research may provide such an opportunity,
with several epidemiologic studies reporting that obese
men are at greater risk for the diagnosis of advanced
stage prostate cancer, disease progression following
treatment, or prostate cancer mortality [4]. In contrast,
while obesity may lead to a more aggressive cancer, obe-
sity also may lower the risk of low-grade or localized
prostate cancer [4,5]. Multiple biological pathways could
be involved in either an increase or decrease in prostate
cancer risk, including effects the inflammatory response,
aromatase expression and shifts in steroid hormone
metabolism, and altered insulin sensitivity [6]. Indeed,
drugs such as metformin used to treat Type 2 diabetes
are also under consideration in prostate cancer treat-
ment [7].
One challenge toward better understanding the rela-
tionship between obesity and prostate cancer is how to
interpret body size measures across diverse groups of
older men. Body mass index (BMI = kg/m2) provides
the most common estimate of body adiposity in cancer
epidemiologic studies. However, BMI is a limited esti-
mator of adipose mass, with recent analyses suggesting
up to 50% of men with body adiposity sufficient to be
classified as obese are instead classified as non-obese
[8,9]. Older men may over-estimate their height [10]
such that BMI is underestimated in studies relying on
self-reported data. Few prostate cancer research studies
measure waist circumference (WC) or waist-hip ratio
(WHR), and the role of centralized adiposity indepen-
dent of BMI in advancing prostate cancer is unclear
[11,12]. Indeed, BMI may be as strongly correlated with
total fat-free mass (FFM) as with total fat mass (FM)
[9], and BMI does not specifically capture the shift
toward centralized fat deposition and abnormal glucose-
insulin metabolism and dyslipidemia that occurs with
aging [13].
Bioelectrical impedance analysis (BIA) provides a fea-
sible and inexpensive approach to estimate body compo-
sition in large-scale epidemiologic studies [14]. Though
BIA is not a reference measurement, studies comparing
body composition measures between BIA and dual-
energy X-ray absorptiometry (DXA) show strong corre-
lation (r ≥ 0.80), such that BIA is able to rank-order
study participants on FM and FFM. With this rank-
ordering, epidemiologic analyses may compare disease
risk between participants with low vs. high exposures.
However, only one prior study investigated the associa-
tion between percent body fat (%BF) from BIA against
prostate cancer, and found no association [12].
The purpose of this study is to expand the investiga-
tion of body composition and prostate cancer by deter-
mining the association between prostate cancer and FM,
FFM, %BF as estimated by BIA. Further understanding
the relationship between FM, FFM, and traditional body
size measures such as BMI with prostate cancer risk
may unify a diverse research literature, and may provide
clues to the most relevant biological pathways linking
BMI to prostate cancer progression.
Methods
Study design
The Nashville Men’s Health Study is a multi-centered,
rapid-recruitment protocol to investigate the clinical,
genetic, and behavioral determinants of prostate cancer
detection, progression, and treatment outcomes. All
recruitment and data collection protocols were approved
by IRBs at Vanderbilt University and the Tennessee Val-
ley Veteran’s Administration. Men referred for prostate
biopsy to Vanderbilt University Medical Center, a large
community urology practice, and the Tennessee Valley
Veterans Administration Medical Center were targeted
for recruitment. These urology clinics receive referrals
from physicians throughout metro Nashville, TN, and
are the primary providers of diagnostic services for uro-
logic disease in the area. Exclusion criteria included age
less than 40 years, a prior prostate cancer diagnosis,
prior prostate surgery, current androgen supplementa-
tion use, or English insufficiency for informed consent.
Recruitment activities, biospecimen collection, and body
size measurements occurred prior to the prostate biopsy
procedure, thus avoiding biases associated with treat-
ment or knowledge of their disease status. Approxi-
mately 90% of eligible men approached for recruitment
consented to participate.
Medical chart review
Data abstraction from urology, surgery, and pathology
medical reports included PSA test history, the number
of prior biopsies, number of prostate cores collected at
biopsy leading to recruitment, and prostate size (ml) at
biopsy. Biopsy Gleason score was abstracted for partici-
pants diagnosed with cancer to define tumor aggressive-
ness. Prior research suggests the relationship between
obesity and prostate cancer is specific to disease stage
or aggressiveness, and we classified cases as having
Gleason 6, Gleason 7, or Gleason 8-10 prostate cancer.
Controls included men identified at biopsy without
prostate cancer, prostatic intraepithelial neoplasia, or
atypical or suspicious foci. A single pathologist reviewed
over 90% of biopsies, and follow-up chart review for 216
prostate cancer cases found that no cases were diag-
nosed with metastatic disease at recruitment.
Measurements
All body size measures were obtained at the time of
recruitment by trained research staff. Weight (kg) (no
shoes, hospital gown) was measured on a calibrated
scale, and height (within 0.1 cm) was measured by
Fowke et al. BMC Cancer 2012, 12:23
http://www.biomedcentral.com/1471-2407/12/23
Page 2 of 8
stadiometer. Body circumferences were measured using
an anthropometric tape measure with built-in tension
meter (Gullick II) to ensure an even tension was admi-
nistered to the tape across participants. Waist circum-
ference was measured at the plane across the iliac crest
and usually represents the narrowest part of the torso.
Hip circumference was measured at the maximum pos-
terior extension of the buttocks. Two measurements at
each site are made in rotational order, with a third mea-
surement if the first two differed by more than 1 cm.
Waist-to-Hip ratio (WHR) was calculated from the aver-
age waist and hip circumference for each participant.
Participants also provided the time of their last food and
beverage intakes.
Total body FFM, FM, and %BF were measured using a
foot-to-foot BIA scale (TBF-310 GS, Tanita Corporation,
Arlington Heights, IL). While wearing a hospital robe,
participants stand on the BIA platform such that the
electrodes are in direct contact with bare feet. Height,
sex, fitness category, and age are entered into the device,
and a small, imperceptible, electric current (500 μA cur-
rent at a frequency of 50 kHz) is applied to one leg. The
resistance to this current was measured at a contact
placed on the opposite leg, and the proprietary software
then estimates total body water, FFM, FM, and %BF.
Statistical analysis
Prior to analysis, we excluded participants reporting
finasteride or dutasteride use that may affect prostate
cancer detection (n = 165), or with an outlying BIA
impedance reading suggesting uncertain quality (impe-
dance > 4 sd from mean, n = 3). Chi-square and Krus-
kal-Wallis tests do not hold distributional assumptions
and were used to compare crude descriptive statistics
between cases and controls. Similarly, we used Spear-
man correlation coefficients with partial adjustment for
age to compare the monotonic relationship between
body size and body composition measures. Case-control
differences in body size and body composition measures
were compared within a linear model adjusting for dif-
ferences in age (continuous), race/ethnicity (white/non-
white), family history of prostate cancer (Yes/No), PSA
level (continuous), prostate volume (continuous), and
current treatment for diabetes (e.g., metformin, insulin,
etc.), cardiovascular disease (e.g., anti-hypertensives, cal-
cium channel blockers, etc.), benign prostatic hyperpla-
sia (alpha-1 adrenergic antagonists), or hyperlipidemia
(e.g., statins, etc.). A p-value of 0.05 or less was consid-
ered statistically significant. Multivariable logistic regres-
sion was used to calculate odds ratios (OR) and 95%
confidence intervals (95% CI) summarizing the associa-
tion between body measurements with prostate cancer.
We analyzed body composition measures as continuous
and as categorized variables. BMI was categorized using
World Health Organization criteria, while other mea-
sures were categorized at the median or quartile values
of the control series. This approach allowed us to
describe associations across the range of data, compare
participants with low vs. higher body size, and to iden-
tify dose-response or non-linear trends that may not be
evident with a continuous variable.
We used a risk-difference approach to ask if the asso-
ciations between BMI or other body size measures could
be mediated by FM, FFM or %BF. For example, we first
calculated an OR for the association between BMI and
prostate cancer, then determined if this OR changed after
including FM to the logistic regression model. A shift in
the OR toward 1.0 after including FM suggested the asso-
ciation between BMI and prostate cancer could be
mediated by that body composition factor.
Results
Controls were approximately the same age as Gleason 6
cases, but 2-5 years younger than Gleason 7 and Glea-
son 8-10 cases, respectively (Table 1). Controls also had
lower blood PSA levels, and a larger prostate size, com-
pared to cases. Gleason 6 cases were most likely to have
a family history of prostate cancer. BPH treatment
tended to decrease with cancer aggressiveness; however
cases and controls did not significantly differ with
regard to race/ethnicity or other factors.
Table 2 summarizes obesity and body composition
measures for cases and controls, adjusted for age and
other factors. Compared to controls, Gleason 8-10 pros-
tate cancer cases had significantly higher levels of BMI,
FM, and FFM. Similarly, Gleason 7 cases had signifi-
cantly higher levels of BMI, WC, WHR, and FFM. Body
size and composition measures were not significantly
associated with Gleason 6 cases. Further adjustment for
time since last food or time since last beverage did not
affect results.
We ran multivariable logistic regression analyses using
body size variables on a continuous scale, or after cate-
gorization to identify trends or thresholds (Table 3).
BMI was marginally associated with Gleason 8-10 pros-
tate cancer (continuous: OR = 1.039 (1.000, 1.081); BMI
> 30: OR = 1.45 (0.93, 2.25)) while a BMI ≥ 35 was sig-
nificantly associated with Gleason 7 cancer (OR = 2.05
(1.19, 1.93)). WC was significantly associated with Glea-
son 8-10 (Q4: OR = 1.90 (1.03, 3.53)) and Gleason 7
cancer (continuous: OR = 1.012 (1.002, 1.022)).
Although there was a significant association between
WHR and Gleason 7 cancer, WHR was not associated
with Gleason 8-10 cancer. BMI, WC, and WHR were
not significantly associated with Gleason 6 prostate
cancer.
Similar analyses of body composition measures found
the highest quartile of FFM was significantly associated
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with Gleason 7 (OR = 1.72 (1.14, 2.61)) and Gleason 8-
10 (OR = 2.91 (1.56, 5.44)) prostate cancer. While a
FFM above the median level was also significantly asso-
ciated with Gleason 6 cancer (OR = 1.31 (1.02, 1.67)),
there was no dose-response trend in the association. FM
as a continuous variable was significantly associated
with Gleason 8-10 cancer (OR = 1.020 (1.004, 1.037)),
while the highest quartile of FM was significantly asso-
ciated with Gleason 7 cancer (OR = 1.52 (1.00, 2.30)). %
BF was not consistently associated with any grade of
prostate cancer.
The correlation between body size and composition
measures for cases and controls and with partial adjust-
ment for age is summarized in Table 4. The correlation
structure was similar across all cancer cases and con-
trols. BMI and WC were strongly correlated with FM
and %BF, and more moderately correlated with FFM.
The correlation between FFM and FM ranged from 0.49
to 0.62 across cases and controls.
In the context of such correlated data, we conducted a
risk-difference analyses to identify whether FM, FFM, or
%BF mediate the association between prostate cancer
and BMI, WC, or WHR. After controlling for FM or
FFM, the association between BMI and Gleason 8-10
was reduced from OR = 1.039 (1.000, 1.081) to OR =
1.010 (0.951, 1.073) or OR = 0.998 (0.946, 1.052),
respectively. Similarly, the increase in Gleason 8-10
prostate cancer associated with greater WC was lost
with control for FM (OR = 1.002 (0.977, 1.027)) or FFM
(OR = 0.995 (0.974, 1.017)). Interestingly, controlling for
FFM produced the greatest change in the BMI or WC
associations with prostate cancer. In contrast, the signif-
icant association between WHR and Gleason 7 prostate
cancer was not substantially affected by controlling for
FM or FFM (OR = 1.203 (1.002, 1.444)); OR = 1.177
(1.000, 1.386), respectively. Controlling for %BF did not
substantially reduce any association.
In full models that include FFM and FM together,
only FFM remained significantly associated with Gleason
7 (continuous: OR = 1.030 (1.008, 1.052)) or Gleason 8-
10 (continuous: OR = 1.044 (1.014, 1.074)); Q4: OR =
2.62 (1.26, 5.45)) prostate cancer (Table 5). FM was not
significantly associated with Gleason 7 or Gleason 8-10
prostate cancer after controlling for FFM, although FM
was marginally protective for Gleason 6 prostate cancer
(OR = 0.987 (0.974, 1.001)) after controlling for FFM.
Discussion
The relevance of interpreting BMI in older men
increases as attention focuses accumulating research
that obesity advances prostate cancer. Such information
serves both to indentify biological pathways in prostate
Table 1 Study population description
Controls (n = 1057) Gleason 6 PC (n = 402) Gleason 7 PC (n = 272) Gleason 8-10 PC (n = 135)
Median 25th-75th Median 25th-75th Median 25th-75th Median 25th-75th p*
Age (years) 64.0 58.0-70.0 64.5 59.0-70.0 66.0 61.0-72.0 69.0 64.0-75.0 < 0.01
PSA (ng/ml) 5.0 4.0-6.8 5.0 4.2-6.7 6.0 4.6-8.4 8.0 5.5-16.4 < 0.01
Prostate Volume (ml) 45.1 33.3-62.8 37.7 28.2-53.0 33.0 25.8-45.0 35.6 26.1-49.6 < 0.01
n % n % n % n %
Non-white ethnicity 103 9.7% 50 12.4% 38 13.9% 14 10.3% 0.17
Family History PC 215 20.3% 112 27.9% 58 21.3% 17 12.5% < 0.01
Diabetes Tx 149 14.1% 50 12.4% 40 14.7% 22 16.3% 0.68
CVD Tx 591 55.9% 244 60.7% 171 62.9% 77 57.0% 0.12
BPH Tx 210 19.9% 74 18.4% 44 16.2% 16 11.9% 0.10
Hyperlipidemia Tx 436 41.3% 180 44.8% 121 55.5% 60 44.4% 0.54
P value from Chi-Square or Kruskal-Wallis test
Table 2 Adjusted mean body size and body composition measures
Controls Gleason 6 PC Gleason 7 PC Gleason 8-10 PC p (vs. control)
Mean 95% CI Mean 95% CI Mean 95% CI Mean 95% CI Gl 6 Gl 7 Gl 8-10
BMI 29.6 29.0, 30.1 29.3 28.7, 29.9 30.2 29.5, 30.9 30.5 29.5, 31.4 0.31 0.05 0.04
WC 105.2 103.7, 106.6 104.1 102.4, 105.8 107.3 105.4, 109.3 107.3 104.7, 109.9 0.99 0.02 0.09
WHR 1.02 1.01, 1.02 1.01 1.00, 1.02 1.03 1.02, 1.04 1.00 1.00, 1.03 0.31 < 0.01 0.68
FM 27.1 25.9, 28.4 26.3 24.7, 27.8 28.0 26.3, 29.7 29.9 27.6, 32.2 0.20 0.28 0.01
FFM 62.9 62.0, 63.8 63.1 62.0, 64.2 64.4 63.1, 65.6 66.2 64.5, 67.9 0.73 0.01 < 0.01
%BF 29.2 28.5, 29.9 28.6 27.7, 29.4 29.4 28.5, 30.4 30.1 28.8, 31.4 0.10 0.64 0.17
Mean values adjusted for age (years), PSA (ng/ml), prostate volume (ml), race (white, non-white), family history (Yes, No/unsure), and current treatment for
diabetes, BPH, CVD, or hyperlipidemia
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carcinogenesis and toward identifying intervention tar-
gets for outcomes research. We utilized BIA as a com-
plementary body measure to better understand the
component of BMI that most affects prostate cancer. In
this large study of over 800 prostate cancer cases, we
found Gleason 7 and Gleason 8-10 prostate cancers
were significantly associated with both FM and FFM.
Furthermore, FFM remained associated with high-grade
prostate cancer after controlling for FM, and FFM
appeared to mediate observed associations between
BMI, WC, or FM.
Results from our investigation of BMI and WC are
consistent with past studies reporting obesity increases
the risk of advanced-stage or high-grade prostate cancer
[4,5]. Higher BMI and WC (continuous or categorized)
were associated with increased risk of Gleason 7 and
Gleason 8-10 prostate cancer, although a limited num-
ber of men with BMI of 35 or more may have limited
observing a clear trend with Gleason 8-10 prostate can-
cer. WHR, in contrast, was associated with Gleason 7
cancer but not with Gleason 8-10 cancer. Furthermore,
BMI, WC, and WHR were not significantly associated
Table 3 Association between body size and body composition with prostate cancer
Gleason 6 PC Gleason 7 PC Gleason 8-10 PC
Measure scale n OR 95% CI n OR 95% CI OR 95% CI
BMI per kg/m2 402 0.989 0.964, 1.015 272 1.025 0.997, 1.055 135 1.039 1.000,1.081
< 25 78 1.0 ref 55 1.0 ref 26 1.0 ref
25-29.9 198 1.17 0.85, 1.61 116 1.12 0.75, 1.64 62 1.63 0.90, 2.91
30-34.9 97 1.05 0.72, 1.51 66 1.24 0.80, 1.93 37 2.24 1.19, 4.23
≥ 35.0 29 0.96 0.57, 1.62 35 2.05 1.19, 1.93 10 1.41 0.54, 3.68
≥ 30 vs. < 30 (ref) 126 0.92 0.71, 1.19 101 1.33 0.98, 1.81 47 1.45 0.93, 2.25
WC per cm 402 0.994 0.984, 1.004 272 1.012 1.002, 1.022 135 1.016 0.999,1.033
Q1 99 1.0 ref 66 1.0 ref 33 1.0 ref
Q2 106 1.07 0.76, 1.49 60 0.98 0.65, 1.49 27 1.22 0.65, 2.29
Q3 120 1.10 0.79, 1.53 75 1.18 0.79, 1.77 39 1.66 0.92, 2.98
Q4 77 0.94 0.65, 1.35 70 1.46 0.95, 2.23 36 1.90 1.03, 3.53
High vs. Low (ref) 197 1.00 0.78, 1.28 145 1.31 0.97, 1.75 75 1.59 1.04, 2.44
WHR per 0.1 unit 402 0.898 0.756, 1.066 272 1.232 1.029, 1.474 135 1.034 0.769,1.388
Q1 100 1.0 ref 51 1.0 ref 29 1.0 ref
Q2 112 0.99 0.71, 1.37 61 0.98 0.63, 1.51 37 1.04 0.57, 1.88
Q3 85 0.85 0.60, 1.21 79 1.44 0.94, 2.20 24 0.88 0.47, 1.67
Q4 105 0.86 0.61, 1.21 80 1.25 0.81, 1.92 45 1.11 0.61, 2.00
High vs. Low (ref) 190 0.86 0.68. 1.10 159 1.36 1.01, 1.83 69 0.98 0.65, 1.49
FM per kg 402 0.993 0.981, 1.004 271 1.010 0.997, 1.024 135 1.020 1.004,1.037
Q1 105 1.0 ref 63 1.0 ref 35 1.0 ref
Q2 111 1.09 0.79, 1.51 67 1.17 0.77, 1.78 24 0.99 0.52, 1.88
Q3 100 1.00 0.71, 1.39 67 1.34 0.88, 2.05 40 2.18 1.22, 3.87
Q4 86 0.88 0.62, 1.25 75 1.52 1.00, 2.30 36 1.65 0.90, 3.03
High vs. Low (ref) 186 0.90 0.71, 1.15 142 1.32 0.98, 1.77 76 1.93 1.25, 2.97
FFM per kg 402 1.006 0.991, 1.021 271 1.029 1.011, 1.048 135 1.047 1.021,1.074
Q1 100 1.0 ref 78 1.0 ref 38 1.0 ref
Q2 96 0.98 0.70, 1.38 63 1.01 0.68, 1.51 25 1.11 0.59, 2.06
Q3 118 1.42 1.02, 1.99 60 1.16 0.76, 1.76 38 2.42 1.34, 4.39
Q4 88 1.14 0.80, 1.64 71 1.72 1.14, 2.61 33 2.91 1.56, 5.44
High vs. Low (ref) 206 1.31 1.02, 1.67 131 1.40 1.04, 1.89 71 2.50 1.60, 3.91
%BF per% 402 0.985 0.968, 1.004 272 1.002 0.980, 1.025 135 1.017 0.987, 1.048
Q1 108 1.0 ref 60 1.0 ref 36 1.0 ref
Q2 109 0.99 0.72, 1.38 68 1.29 0.85, 1.96 26 1.05 0.57, 1.93
Q3 108 1.04 0.75, 1.44 84 1.63 1.08, 2.45 40 1.65 0.94, 2.92
Q4 77 0.71 0.50, 1.02 60 1.07 0.70, 1.65 33 1.21 0.66, 2.19
High vs. Low (ref) 185 0.88 0.69, 1.12 144 1.18 0.88, 1.58 73 1.39 0.92, 2.12
All analyses adjusted for age (years), PSA (ng/ml), prostate volume (ml), race (white, non-white), family history (Yes, No/unsure), and current treatment for
diabetes, CVD, BPH, or hyperlipidemia. Q = quartile. High vs Low defined at median value
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with Gleason 6 cancer. Interestingly, the BMI or WC
associations were generally stronger for Gleason 8-10
prostate cancer than for Gleason 7 cancer, consistent
with promoting a more aggressive phenotype. Obesity
increases oxidative stress, estrogen and leptin levels,
inflammatory responses, energy availability, and insulin
insensitivity, while decreasing adiponectin [6,15]. Thus,
observed associations could be reasonably interpreted as
deriving from the effects of excess total or centralized
body adiposity.
We used BIA to investigate the relationship between
body adiposity and prostate cancer. BIA is an accessible
and inexpensive body composition method and provides
an opportunity to confirm relationship between FM and
prostate cancer. However it must be recognized that
body composition estimates from BIA do not always
equal those derived from DXA or other reference meth-
ods [16-18]. Furthermore, the BIA prediction equations
are less accurate among persons with either a very high
or low BMI, and cannot address differences in hydration
or electrolyte levels, or chronic renal failure [17]. This
error limits BIA as a quantitative assessment method for
many individuals wishing to know their true body com-
position. Despite these limitations, BIA estimates of
body composition are strongly correlated with those
from DXA (r ≥ 0.80) [16-19]. In unpublished data, we
found strong correlations between foot-to-foot BIA and
DXA (FM: r = 0.96, FFM: r = 0.82, %BF: r = 0.85, n =
31 men ages 40-85 years). These studies illustrate that
BIA has limitations, but also that BIA is sufficient to
rank-order participants, allowing us to ask if those with
a higher level of exposure have a different prostate can-
cer risk than those with a low level.
Contrary to our original hypothesis, we found that
FFM best mediated the statistical association between
BMI, WC, and FM with high-grade prostate cancer.
This does not mean, however, that greater FFM
increases the risk of prostate cancer, but instead prob-
ably reflects shared genetic, hormonal, or nutritional
factors for both the maintenance of lean body mass and
prostate carcinogenesis. For example, pituitary growth
hormone (GH) induces insulin-like growth factor 1
(IGF1) from the liver and muscle to increase skeletal
muscle mass [20]. GH and IGF1 levels decline with
aging, concordant with loss of muscle and bone mass
and an increase in fat deposition and BMI [21], and
selected studies have reported an association between
prostate cancer and blood IGF1 [22,23] or genetic var-
iants in IGF1 [24] or IGFBP3 [25]. Interestingly, the
PI3K/AKT/mTOR pathway plays an important role in
translating IGF1 signals to protein synthesis and inhibit-
ing muscle degradation and sarcopenia, and this path-
way also regulates steroid, protein, ATP, and fatty acid
synthesis critical in prostate carcinogenesis [20,26,27].
Alternatively, androgens almost certainly play a role in
prostate cancer progression [28], and circulating testos-
terone levels decline with aging and are associated with
centralized fat deposition and loss of lean mass [29,30].
Table 4 Partial Spearman correlation coefficients
(adjusted for age) between body size and body
composition in controls, and Gleason 6, Gleason 7, and
Gleason 8-10 prostate cancer cases
WC WHR FM FFM %BF
BMI Control 0.88 0.50 0.90 0.60 0.83
Gleason 6 0.88 0.56 0.89 0.55 0.82
Gleason 7 0.91 0.58 0.91 0.71 0.80
Gleason 8-10 0.82 0.42 0.80 0.53 0.77
WC Control 0.72 0.89 0.62 0.80
Gleason 6 0.75 0.88 0.57 0.80
Gleason 7 0.75 0.89 0.69 0.79
Gleason 8-10 0.66 0.83 0.62 0.79
WHR Control 0.51 0.27 0.51
Gleason 6 0.57 0.21 0.57
Gleason 7 0.57 0.32 0.54
Gleason 8-10 0.41 0.27 0.42
FM Control 0.57 0.93
Gleason 6 0.50 0.94
Gleason 7 0.62 0.92





All p < 0.001
Table 5 Separating the effects of fat mass and fat free
mass on prostate cancer
Gleason 6 PC Gleason 7 PC Gleason 8-10 PC
OR 95% CI OR 95% CI OR 95% CI
FM* kg 0.987 0.974, 1.001 0.999 0.983, 1.015 1.005 0.983, 1.027
FFM kg 1.015 0.997, 1.033 1.030 1.008, 1.052 1.044 1.014, 1.074
OR 95% CI OR 95% CI OR 95% CI
FM** Q1 1.0 reference 1.0 reference 1.0 reference
Q2 0.99 0.70, 1.40 1.13 0.73, 1.74 0.79 0.40, 1.56
Q3 0.86 0.60, 1.24 1.19 0.75, 1.89 1.48 0.76, 2.88
Q4 0.75 0.50, 1.11 1.24 0.76, 2.01 0.97 0.47, 1.98
FFM Q1 1.0 reference 1.0 reference 1.0 reference
Q2 1.03 0.72, 1.46 0.96 0.63, 1.46 1.02 0.52, 1.97
Q3 1.54 1.07, 2.21 1.07 0.68, 1.69 2.18 1.15, 4.27
Q4 1.32 0.88, 2.00 1.53 0.94, 2.50 2.62 1.26, 5.45
Table 5 includes analyses that describe the association between FFM or FM
on PC after controlling for either FM or FFM. Analyses evaluate FM and FFM
as either continuous variables or at quartiles
* PC = FM (continuous), FFM (continuous), age, prostate volume, PSA, race,
family history, and current treatment for diabetes, CVD, BPH, and
hyperlipidemia
** PC = FM (Quartiles), FFM (Quartiles), age, prostate volume, PSA, race, family
history, and current treatment for diabetes, CVD, BPH, and hyperlipidemia
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Men with sufficient androgen activity to support lean
body mass and control fat deposition in aging may also
have increased prostate cancer risk. Indeed, androgen
and GH/IGF1 activities may both be involved, such that
FFM may reflect the phenotypic marker of cumulative
systemic systems involved in prostate carcinogenesis
[31]. Interestingly, this does not preclude obesity as a
risk factor for high-grade prostate cancer. Many of these
effects of obesity operate through the PI3K/ATK/mTOR
(e.g., insulin) or LkB-AMPK/mTOR (e.g., adiponectin)
pathways [26], such that obesity affects pathways which
may, in turn, support FFM retention. We also observed
a non-significant protective association between FM and
Gleason 6 cancer [5] that became stronger after control-
ling for FFM, perhaps suggesting that FFM is somewhat
obscuring the ability to identify an association between
obesity and low-grade prostate cancer.
Strengths of this investigation include a study popula-
tion with a sufficient number of high-grade cases for
analysis. Body size and body composition measures were
ascertained by trained staff and prior to diagnosis to
prevent reporting error or treatment effects [10].
Although prostate biopsy may miss a cancer, potential
bias derived from latent cancer within the control group
was minimized because all controls were without cancer
at biopsy. BMI is associated with lower blood PSA levels
and a larger prostate size, such that potential stage-spe-
cific associations between obesity and prostate cancer
may be an artifact of factors that influence the ability to
detect prostate cancer [32]. However, the study design
controls for selective healthcare access, and we con-
trolled for PSA levels, prostate size, and obesity-related
diseases that may affect prostate cancer detection or
grading.
The study has several limitations. Although it is unli-
kely that FFM or FM levels are a consequence of a
latent or undiagnosed prostate tumor, we cannot say
with certainty whether current or past FFM and FM is
most relevant. Addressing this would require a prospec-
tive study with repeated data collection during follow-
up. BIA was chosen as a body composition assessment
method because it is feasible for large epidemiologic stu-
dies, but as discussed above, BIA is susceptible to cer-
tain errors. Our results were not affected by the time
between BIA measurement and the participant’s last
meal or last liquid. We were unable to evaluate the
impact of kidney function, but have no reason to believe
that kidney function differed between cases and con-
trols. The majority of participants were white, and
therefore our results may not generalize to other race/
ethnicities. Chance findings can never be entirely ruled
out. Replication is necessary to confirm our findings and
to extent these results to other race/ethnic groups.
Conclusions
In summary, multiple body size indices were associated
with high-grade prostate cancer. Furthermore, FFM
remained significantly associated with high-grade pros-
tate cancer after controlling for FM, BMI, and WC.
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